5-HT1B receptor subtype and aging in rat resistance vessels

被引:4
|
作者
Froldi, Guglielmina
Montopoli, Monica
Zanetti, Miriam
Dorigo, Paola
Caparrotta, Laura
机构
[1] Univ Padua, Dept Pharmacol & Anaesthesiol, I-35131 Padua, Italy
[2] Univ Padua, Dept Histol Microbiol & Med Biotechnol, Padua, Italy
关键词
`Silent' 5-HT1B receptor; 5-HT2A receptor; aging; rat resistance vessels; sumatriptan; caudal artery;
D O I
10.1159/000109297
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of 5-hydroxytryptamine ( 5-HT), 5-carboxamidotryptamine, and sumatriptan on rat caudal arteries were examined, with the goal of finding experimental conditions useful in enhancing the `silent' 5-HT1B receptor subtype. It was shown that both reserpine treatment and K+ depolarization increased the vasoconstriction by 5-HT receptor agonists. The role of the 5-HT2A receptor in vasoconstriction was examined using ritanserin (50 nmol/l), a selective 5-HT2A antagonist, whereas that of the `silent' 5-HT1B receptor was examined using SB-224289 (0.2 mu mol/l), a selective 5-HT1B receptor antagonist. The influence of age on the `silent' 5-HT1B receptor subtype was also investigated; for this, the effect of sumatriptan, a selective 5-HT1B/1D agonist, was tested on arterial tissues of both young and old rats which had been either K+ depolarized or reserpine treated or both. It was found that aging strongly shifted the concentration-vasoconstriction curve generated by sumatriptan to the left, also increasing the maximum contractile response, mainly in reserpine-treated tissues. RT-PCR was used to study the expression of 5-HT1B and 5-HT2A receptors in both young and old tissues. The results support the idea that reserpine-treated and K+-depolarized caudal arteries from old rats can be a pharmacological model which is useful in highlighting the `silent' 5-HT1B receptor subtype. Copyright (C) 2008 S. Karger AG, Basel.
引用
收藏
页码:70 / 78
页数:9
相关论文
共 50 条
  • [41] Spinal sumatriptan inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors
    Munoz-Islas, Enriqueta
    Lozano-Cuenca, Jair
    Gonzalez-Hernandez, Abimael
    Ramirez-Rosas, Martha B.
    Sanchez-Lopez, Araceli
    Centurion, David
    MaassenVanDenBrink, Antoinette
    Villalon, Carlos M.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 615 (1-3) : 133 - 138
  • [42] Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors
    Munoz-Islas, E.
    Gupta, S.
    Jimenez-Mena, L. R.
    Lozano-Cuenca, J.
    Sanchez-Lopez, A.
    Centurion, D.
    Mehrotra, S.
    MaassenVanDenBrink, A.
    Villalon, C. M.
    BRITISH JOURNAL OF PHARMACOLOGY, 2006, 149 (01) : 82 - 91
  • [43] Effects of avitriptan, a new 5-HT1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential
    P. R. Saxena
    Peter De Vries
    W. Wang
    Jan P. C. Heiligers
    Antoinette MaassenVanDenBrink
    Willem A. Bax
    Frank D. Yocca
    Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 355 : 295 - 302
  • [44] The Phe-124-Cys and A-161T variants of the human 5-HT1B receptor gene are not major determinants of the clinical response to sumatriptan
    Mehrotra, Suneet
    Vanmolkot, Kaate R. J.
    Frants, Rune R.
    van den Maagdenberg, Arn M. J. M.
    Ferrari, Michel D.
    MaassenVanDenBrink, Antoinette
    HEADACHE, 2007, 47 (05): : 711 - 716
  • [45] Lack of sumatriptan-induced aortic contraction or relaxation:: 5-HT1B receptor protein detected in endothelium and smooth muscle of vasa vasorum but not aorta
    Cohen, ML
    Galbreath, EJ
    Schenck, KW
    Li, DQ
    Hoffman, BJ
    Bhattacharya, A
    RECEPTORS & CHANNELS, 2002, 8 (02) : 71 - 78
  • [46] BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential
    Saxena, PR
    De Vries, P
    Heiligers, JPC
    Bax, WA
    VandenBrink, AM
    Yocca, FD
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 351 (03) : 329 - 339
  • [47] Effects of avitriptan, a new 5-HT1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential
    Saxena, PR
    DeVries, P
    Wang, W
    Heiligers, JPC
    VanDenBrink, AM
    Bax, WA
    Yocca, FD
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 355 (02) : 295 - 302
  • [48] THE 5-HT1-LIKE RECEPTOR MEDIATING THE INCREASE IN CANINE EXTERNAL CAROTID BLOOD-FLOW - CLOSE RESEMBLANCE TO THE 5-HT1D SUBTYPE
    VILLALON, CM
    TERRON, JA
    BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (01) : 13 - 20
  • [49] Regulation of heterologously expressed 5-HT1B receptors coupling to potassium channels in AtT-20 cells
    Heblinski, Marika
    Bladen, Christopher
    Connor, Mark
    BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (03) : 451 - 465
  • [50] Involvement of 5-HT1B/1D receptors in the inflammatory response and oxidative stress in intestinal ischemia/reperfusion in rats
    Gharishvandi, Fatemeh
    Abdollahi, Alireza
    Shafaroodi, Hamed
    Jafari, Razieh Mohammad
    Pasalar, Parvin
    Dehpour, Ahmad Reza
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 882